To be clear, the doubt I've raised is that TAF regimen (‘Quad Prime’) will differ from Viread regimen (Stribild) in safety/efficacy terms. No doubt it is a crucially important compound for GILD in its patent extension strategy. The question I've pointed to is important because if TAF proves to be superior to Viread, it would be easier for GILD to switch patients to the TAF regimen even before Viread goes generic and keep them after generic competition.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.